Drug Search Results
More Filters [+]

Beraprost

Alternative Names: beraprost
Latest Update: 2024-04-25
Latest Update Note: PubMed Publication

Product Description

Beraprost sodium (beraprost) is a stable, orally active prostacyclin analogue with vasodilatory, antiplatelet and cytoprotective effects. Beraprost acts by binding to prostacyclin membrane receptors ultimately inhibiting the release of Ca2+ from intracellular storage sites. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/11790158/)

Mechanisms of Action: PGI2 Angalogue

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Indonesia | Japan | Korea | Philippines | Thailand

Approved Indications: None

Known Adverse Events: None

Company: Sino Biopharmaceutical
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Beraprost

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Chronic Pain|Intermittent Claudication

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20230133

P2

Completed

Chronic Pain|Intermittent Claudication

2023-04-11

Recent News Events